Drug Profile
SPK 3006
Alternative Names: RG-6359; SPK-3006; SPK-GAALatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Spark Therapeutics
- Class Gene therapies
- Mechanism of Action Alpha glucosidase expression stimulants; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Glycogen storage disease type II
Most Recent Events
- 25 Apr 2022 Phase-II clinical trials in Glycogen storage disease type II in France (IV) as of April 2022 (Roche pipeline, April 2022)
- 25 Apr 2022 Phase-II clinical trials in Glycogen storage disease type II in USA (IV) as of April 2022 (Roche pipeline, April 2022)
- 05 Aug 2020 Spark Therapeutics re-initiates enrolment in the phase I/II RESOLUTE trial in Glycogen storage disease Type II in USA (NCT04093349) (EudraCT 2019-001283-30)